Carey_2011_BMC.Cell.Biol_12_20

BACKGROUND: The amyloid precursor protein (APP) is cleaved by beta- and gamma-secretases to generate toxic amyloid beta (Abeta) peptides. Alternatively, alpha-secretases cleave APP within the Abeta domain, precluding Abeta formation and releasing the soluble ectodomain, sAPPalpha. We previously showed that inhibition of the GTPase dynamin reduced APP internalization and increased release of sAPPalpha, apparently by prolonging the interaction between APP and alpha-secretases at the plasma membrane. This was accompanied by a reduction in Abeta generation. In the present study, we investigated whether surface expression of the alpha-secretase ADAM (a disintegrin and metalloprotease)10 is also regulated by dynamin-dependent endocytosis.
RESULTS: Transfection of human embryonic kidney (HEK) cells stably expressing M3 muscarinic receptors with a dominant negative dynamin I mutant (dyn I K44A), increased surface expression of both immature, and mature, catalytically active forms of co-expressed ADAM10. Surface levels of ADAM10 were unaffected by activation of protein kinase C (PKC) or M3 receptors, indicating that receptor-coupled shedding of the ADAM substrate APP is unlikely to be mediated by inhibition of ADAM10 endocytosis in this cell line. Dyn I K44A strongly increased the formation of a C-terminal fragment of ADAM10, consistent with earlier reports that the ADAM10 ectodomain is itself a target for sheddases. The abundance of this fragment was increased in the presence of a gamma-secretase inhibitor, but was not affected by M3 receptor activation. The dynamin mutant did not affect the distribution of ADAM10 and its C-terminal fragment between raft and non-raft membrane compartments.
CONCLUSIONS: Surface expression and limited proteolysis of ADAM10 are regulated by dynamin-dependent endocytosis, but are unaffected by activation of signaling pathways that upregulate shedding of ADAM substrates such as APP. Modulation of ADAM10 internalization could affect cellular behavior in two ways: by altering the putative signaling activity of the ADAM10 C-terminal fragment, and by regulating the biological function of ADAM10 substrates such as APP and N-cadherin.